BioLineRx Ltd. (NASDAQ: BLRX) Earnings Report and Clinical Development Update

BioLineRx reported an earnings per share (EPS) of -0.38, matching the estimated EPS, and generated revenue of $514,000, surpassing the estimated revenue.The company is advancing its clinical pipeline with the upcoming Phase 1/2a clinical trial of GLIX1 for glioblastoma (GBM).Despite financial challenges, including a negative P/E ratio of approximately -3.24 and a debt-to-equity ratio of about 0.58, BioLineRx shows growth potential with a price-to-sales ratio of 0.84.BioLineRx Ltd. (NASDAQ:BLRX) is a biophar ...